Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 2 N=76 Vilazodone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 5.5; 3.6 percentage of UDS
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
N/A N=269 Effect of Medical Marijuana on Neurocognition and Escalation of Use
Pain · Insomnia · Depression
Primary: Mean Difference in Number of Cannabis Use Disorder Symptoms Averaged Over 2, 4, and 12 Weeks — 0.39; 0.12 score on a scale — p=<0.001
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Phase 1 N=8 Facilitating the Behavioral Treatment of Cannabis Use Disorder
Cannabis Dependence
Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants
Phase 4 N=175 Buspirone Treatment for Marijuana Dependence
Marijuana Dependence
Primary: Percent Marijuana-negative Urine Drug Screens (UDS) — 7.2; 6.4 percentage of UDS
Phase 3 N=127 The Role of Sleep in the Treatment of Cannabis Use Disorders
Drug Addiction
Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed
N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
N/A N=75 Development and Efficacy Test of Computerized Treatment for Marijuana Dependence
Marijuana Abuse and Dependence
Primary: Consecutive Weeks of Marijuana Abstinence — 3.55; 2.82; 0.78 consecutive weeks of abstinence — p=<0.05
Phase 3 N=28 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
Cannabis Use Disorder · Attention-deficit/Hyperactivity Disorder
Primary: Marijuana Abstinence — 0; 2 Participants
Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
N/A N=107 Project CheckUP: A Brief Behavioral Intervention for Quitline Callers Who Use Marijuana (MJ) and Tobacco
Smoking Cessation · Marijuana Use
Primary: Number of Calls Completed — 123; 141 Total number of calls
Phase 2 N=130 Quetiapine Pharmacotherapy for Cannabis Dependence
Cannabis Dependence
Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars
N/A N=25 Impact of Reduced Cannabis Use on Functional Outcomes
Cannabis · Cannabis Use
Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants
Phase 2 N=70 Treatment for Cannabis Withdrawal and Dependence
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
N/A N=20 Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
Cannabis Use Disorder
Primary: Number (%) of Participants Who Started and Completed Treatment — 8; 8 Participants
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 2 N=14 Effects of Marijuana on Symptoms of OCD
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
Phase 1 N=12 Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
Schizophrenia · Dual Diagnosis · Schizoaffective Disorder
Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score
Phase 2 N=157 Marijuana's Impact on Alcohol Motivation and Consumption
Alcohol Drinking · Marijuana
Primary: Alcohol Craving — 2.54; 2.64; 2.65; 2.55 units on a scale
Phase 3 N=52 Nabilone for Cannabis Dependence: A Pilot Study
Cannabis Dependence · Marijuana Dependence
Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
Phase 2 N=61 Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
Marijuana Dependence
Primary: Physiological Changes in Response to Cue-induced Craving. — 5.65 T value
Phase 2 N=228 Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
Cannabis Use Disorder
Primary: Time Line Follow Back (TLFB) for Cannabis Use — 1.921; 1.768; 1.201; 1.066 times/day of self-reported cannabis use
N/A N=60 Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)
Cannabis · Cannabis Use
Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
Phase 4 N=127 Nicotine Patch for Marijuana Withdrawal
Marijuana Dependence
Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale